Literature DB >> 15862527

Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake.

Caroline R Abbott1, Caroline J Small, Adam R Kennedy, Nicola M Neary, Arshia Sajedi, Mohammad A Ghatei, Stephen R Bloom.   

Abstract

The gastrointestinal-derived hormone peptide YY (PYY) is released from intestinal L-cells post-prandially in proportion to calorie intake, and modulates food intake. Peripheral administration of PYY((3-36)) reduces food intake and body weight in rodents and suppresses appetite and food intake in humans. PYY((3-36)) is hypothesised to inhibit food intake via activation of the auto-inhibitory pre-synaptic neuropeptide Y (NPY) Y2 receptor (Y2R) present on arcuate (ARC) NPY neurons. We aimed to investigate the feeding effect of PYY((3-36)) following blockade of ARC Y2R, using the specific receptor antagonist BIIE0246, in the rat. We found that pre-treatment with BIIE0246 (1 nmol) into the ARC attenuated the reduction in feeding observed following intraperitoneal injection of PYY((3-36)) (7.5 nmol/kg) (0-1 h food intake: BIIE0246/PYY((3-36)): 3.8 +/- 0.4 g; vs. Vehicle/PYY((3-36)): 2.7 +/- 0.2 g; P < 0.05). We found plasma PYY levels to be maximal at 120 min post-initiation of feeding. On investigation of the endogenous role of the Y2R, we found that ARC administration of BIIE0246 alone significantly increased feeding in satiated rats compared to vehicle-injected controls (0-1 h food intake: BIIE0246: 4.1 +/- 0.7 g; vs. vehicle: 1.7 +/- 0.7 g; P < 0.05), suggesting that Y2R antagonism disinhibits the NPY neuron thus stimulating feeding in otherwise satiated rats. These studies suggest that the Y2R plays an important role in post-prandial satiety and provide further insight into the mechanisms of action of PYY((3-36)).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15862527     DOI: 10.1016/j.brainres.2005.02.065

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  48 in total

1.  Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.

Authors:  Miia Kovalainen; Juha Mönkäre; Ermei Mäkilä; Jarno Salonen; Vesa-Pekka Lehto; Karl-Heinz Herzig; Kristiina Järvinen
Journal:  Pharm Res       Date:  2011-10-27       Impact factor: 4.200

Review 2.  Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds.

Authors:  Konstantinos Michalakis; Carel le Roux
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

Review 3.  Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin.

Authors:  Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye
Journal:  Mol Cell Endocrinol       Date:  2018-11-02       Impact factor: 4.102

Review 4.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 5.  Central dysregulations in the control of energy homeostasis and endocrine alterations in anorexia and bulimia nervosa.

Authors:  A Torsello; F Brambilla; L Tamiazzo; I Bulgarelli; D Rapetti; E Bresciani; V Locatelli
Journal:  J Endocrinol Invest       Date:  2007-12       Impact factor: 4.256

Review 6.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  A role for PYY3-36 in GLP1-induced insulin secretion.

Authors:  Amandine Gautier-Stein; Gilles Mithieux
Journal:  Mol Metab       Date:  2013-06-13       Impact factor: 7.422

Review 8.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

9.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

10.  GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.

Authors:  Jianping Ye; Zheng Hao; Michael B Mumphrey; R Leigh Townsend; Laurel M Patterson; Nicholas Stylopoulos; Heike Münzberg; Christopher D Morrison; Daniel J Drucker; Hans-Rudolf Berthoud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-15       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.